openPR Logo
Press release

Squamous Non-small Cell Lung Cancer Market, 2021-2031 by Roots Analysis

12-30-2021 05:10 AM CET | Health & Medicine

Press release from: Roots Analysis

Squamous Non-small Cell Lung Cancer Market, 2021-2031 by Roots

Advances in molecular biology and tumor immunology have enabled the development of NSCLC targeting therapies, which have the ability to impede cancer growth by altering chemical reactions associated with oncogenic driver mutations

Roots Analysis has announced the addition of “Squamous Non-small Cell Lung Cancer Market, 2021-2031” report to its list of offerings.

Success of approved squamous non-small cell lung cancer therapies, such as Keytruda®, Opdivo® and Portrazza®, has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of these therapies to effectively treat NSCLC, an aggressive form of lung carcinoma, justifies its potential as a promising disease management recourse. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.

To order this 122+ page report, which features 81+ figures, please visit https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html

Key Market Insights

More than 85 product candidates are being investigated to treat metastatic or advanced squamous NSCLC patients
More than 78% of the therapies are being evaluated in early stages, either as monotherapies or in combination with other products. Further, majority of these therapies (45%) are designed for administration via the intravenous route. It is worth highlighting that, till date, five biologics and one small molecule have been approved for the treatment of squamous NSCLC.

Several big pharma players have an advanced pipeline of drugs targeting squamous NSCLC
Over 34 companies engaged in this domain represent large / very large businesses. Although biologics emerged as the most prominent type of molecule in the overall pipeline, big pharma players were observed to prefer developing small molecules against lung carcinomas. Interestingly, 53% of such firms are based in North America.

240+ clinical trials for squamous NSCLC therapy focused clinical trials were registered, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 56%, during the period 2017-2020. Of the total number of trials registered, close to 40% have already been completed, while 30% of the studies are actively recruiting participants.

Partnership activity has grown at an annualized rate of nearly 48%, between 2017 and 2020
Maximum number of partnerships were observed in 2020, indicating a recent increase in the activity. Majority of these agreements were reported to be product development and commercialization agreements, representing over 35% of the total number of instances.

The squamous non-small cell lung cancer market is projected to grow at a CAGR of 10.8% till 2030
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and growing demand for targeted and personalized therapeutic modalities. Biologics currently capture a significant market share, with the maximum revenue generation potential being associated with monoclonal antibodies; this trend is unlikely to change in the foreseen future.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html

Key Questions Answered
 What are the prevalent R&D trends related to squamous non-small cell lung cancer?
 What are the key challenges faced by stakeholders engaged in this domain?
 What are the principal therapies being developed by the industry players?
 Who are the leading industry and non-industry players in this market?
 What are the contributions of big pharma players in this field?
 What are the key geographies where research on squamous non-small cell lung cancer is being conducted?
 Who are the key investors in this domain?
 Who are the key opinion leaders / experts in this field?
 What kind of partnership models are commonly adopted by industry stakeholders?
 What are the factors that are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the non-small cell lung cancer market has been analyzed across the following segments:

 Type of Molecule
 Biologics
 Small molecules

 Type of Therapy
 Monotherapy
 Combination therapy

 Route of Administration
 Intravenous
 Intradermal
 Oral
 Subcutaneous

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific and the Rest of World

The research includes detailed profiles of 22+ drugs being developed by key players (listed below); each profile features an overview of the developer, details related to its financial information (if available), recent developments and an informed future outlook.
 Akesobio
 Alphamab Oncology
 Arcus Biosciences
 Astrazeneca
 BeiGene
 Boehringer Ingelheim
 Bristol Myers Squibb
 Cadila Pharmaceuticals
 Eli Lilly
 GlaxoSmithKline
 Hengrui Medicine
 Henlius
 Innovent Biologics
 Junshi Biosciences
 Macrogenics
 Merck
 Novartis
 Pfizer
 Regeneron
 Roche
 SinoCellTech

For additional details, please visit
https://www.rootsanalysis.com/reports/squamous-non-small-cell-lung-cancer-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. RAS Targeting Therapies Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com


Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

30.65, A 430, Bestech Business Towers,, Sector 66, Sahibzada Ajit Singh Nagar, Punjab 160066

We specialise in analysing areas which have lacked quality research so far or require more focussed understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Squamous Non-small Cell Lung Cancer Market, 2021-2031 by Roots Analysis here

News-ID: 2513697 • Views: 483

More Releases from Roots Analysis

Novel Drug Reconstitution Systems Market, 2021-2030
In 2018, seven out of ten top-selling prescription medicines were biologics. The liquid formulations of biologics are not much stable and tend to lose efficacy with time due to the changes in their pharmacokinetic and pharmacodynamic properties. Therefore, lyophilization of such drugs is essential before their storage. Around 50% of the biologics intended for parenteral administration are available in lyophilized form, which require reconstitution before administration. To Request for sample -
The TIL-based therapies market is projected to be worth over USD 4.3 billion, by …
Driven by the potential to confer sustained therapeutic effects and thereby, facilitate prolonged periods of remission, TIL-based therapies have received significant financial support, and promising leads are poised to soon achieve blockbuster status Roots Analysis has announced the addition of “TIL-based Therapies Market, 2021-2030” report to its list of offerings. Given the frequently reported inadequacies of conventional cancer therapies and the growing need for personalized medicine, there is a marked surge
The novel ocular drug delivery devices market is projected to grow at a CAGR of …
The delivery of drugs in ocular regions is known to be considerably more challenging; several pharmaceutical companies are actively undertaking initiatives to identify novel approaches for safe and efficient administration of therapies to eyes Roots Analysis has announced the addition of the “Novel Ocular Drug Delivery Devices Market, 2021 – 2030” report to its list of offerings. Over the years, a number of companies have developed several novel and advanced drug
The progressive supranuclear palsy (PSP) therapies market, is anticipated to gro …
The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy London Roots Analysis has announced the addition of “Progressive Supranuclear Palsy Therapies Market, 2021-2030” report to its list of offerings. Presently, there is no cure for PSP and the effectiveness of prescribed generic

All 5 Releases


More Releases for NSCLC

Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forec …
Market Research Report Store offers a latest published report on Targeted Drug EGFR RTK Inhibitors for NSCLC Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 158 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/624297/global-targeted-drug-egfr-rtk-inhibitors   In 2018,
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot: NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit
Non-Small Cell Lung Cancer (Nsclc)-China Drug Forecast and Market Analysis To 20 …
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast And Marke …
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva
The NSCLC Market Will Be Valued At $10.9 Billion In 2021 At A CAGR Of 8.5%
Researchmoz added Most up-to-date research on "Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line" to its huge collection of research reports. Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need